The Beneficial Role of Sunitinib in Tumor Immune Surveillance by Regulating Tumor PD‐L1
Abstract Immune checkpoints blockades have shown promising clinical effects in various malignancies, but the overall response rate is low. Here, the immune features are comprehensively characterized in >10 000 cancer patients from The Cancer Genome Atlas and significantly positive correlations ar...
Main Authors: | Hui Li, Xinwei Kuang, Long Liang, Youqiong Ye, YongChang Zhang, Jialu Li, Fangyu Ma, Juan Tao, Guang Lei, Shuang Zhao, Juan Su, Nong Yang, Cong Peng, Xiaowei Xu, Mien‐Chie Hung, Leng Han, Hong Liu, Jing Liu, Xiang Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-01-01
|
Series: | Advanced Science |
Subjects: | |
Online Access: | https://doi.org/10.1002/advs.202001596 |
Similar Items
-
Potential for use sunitinib in pancreatic neuroendocrine tumors
by: A. A. Markovich, et al.
Published: (2019-06-01) -
Sunitinib in pancreatic neuroendocrine tumors. Clinical case
by: A. A. Markovich, et al.
Published: (2019-12-01) -
Sunitinib in Patients with Metastatic Renal Cell Carcinoma with Favorable Risk: Be Aware of PD-L1 Expression
by: Ilya Tsimafeyeu
Published: (2024-09-01) -
Pneumatosis cystoides intestinalis linked to sunitinib treatment for renal cell carcinoma
by: Hiroyuki Shikuma, et al.
Published: (2019-11-01) -
Sunitinib for adenocarcinoma of the rete testis: a case report
by: Kezhen Li, et al.
Published: (2024-04-01)